GUT 1
Alternative Names: CHST15 dsRNA; CHST15 siRNA; GUT-1; MT-5745; STNM 01Latest Information Update: 18 Jul 2024
At a glance
- Originator Stelic Institute & Co
- Developer Gut; Mitsubishi Tanabe Pharma Corporation; Sameshima Hospital; Stelic Institute & Co
- Class Anti-inflammatories; Antifibrotics; Antineoplastics; Antiulcers; Small interfering RNA
- Mechanism of Action CHST15 protein expression inhibitors; RNA interference
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I/II Pancreatic cancer
- Discontinued Crohn's disease; Ulcerative colitis
Most Recent Events
- 18 Jul 2024 TME therapeutics completes a phase-I/II clinical trials in Pancreatic cancer (Inoperable/Unresectable, Second-line therapy or greater, Combination therapy) in Japan (Intratumoural) prior to July 2024 (jRCT2031190055) (TME Therapeutics pipeline, July 2024)
- 31 May 2024 Preclinical trials in pancreatic cancer in Japan (Intratumoural) prior to May 2024
- 31 May 2024 Pharmacodynamics data from a preclinical study in Pancreatic cancer presented at the 60th Annual Meeting of the American Society of Clinical Oncology (ASCO-2024)